LP
BMRN icon

LMR Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

LMR Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.4M Buy
324,939
+305,761
+1,594% +$17.8M 0.04% 235
2025
Q4 		$1.14M Buy
+19,178
New +$1.04M ﹤0.01% 957
2025
Q1 		– Sell
-4,418
Closed -$297K – 1389
2024
Q4 		$290K Sell
4,418
-70,730
-94% -$4.74M ﹤0.01% 912
2024
Q3 		$5.28M Sell
75,148
-47,969
-39% -$4.01M 0.04% 353
2024
Q2 		$10.1M Buy
123,117
+44,917
+57% +$3.74M 0.09% 205
2024
Q1 		$6.83M Hold
78,200
– – 0.07% 243
2023
Q4 		$7.54M Buy
78,200
+1,835
+2% +$162K 0.09% 233
2023
Q3 		$6.76M Buy
76,365
+41,354
+118% +$3.68M 0.08% 223
2023
Q2 		$3.03M Sell
35,011
-39,408
-53% -$3.71M 0.03% 306
2023
Q1 		$7.24M Buy
74,419
+17,494
+31% +$1.81M 0.11% 208
2022
Q4 		$5.89M Buy
56,925
+2,040
+4% +$192K 0.1% 238
2022
Q3 		$4.65M Buy
54,885
+18,932
+53% +$1.69M 0.09% 293
2022
Q2 		$2.98M Sell
35,953
-54,650
-60% -$4.35M 0.05% 415
2022
Q1 		$6.99M Buy
90,603
+55,448
+158% +$4.64M 0.08% 258
2021
Q4 		$3.11M Buy
+35,155
New +$2.9M 0.03% 350
2021
Q3 		– Sell
-7,895
Closed -$659K – 1009
2021
Q2 		$659K Hold
7,895
– – 0.01% 628
2021
Q1 		$596K Sell
7,895
-20,605
-72% -$1.68M 0.01% 597
2020
Q4 		$2.5M Buy
+28,500
New +$2.26M 0.04% 178
2019
Q4 		– Sell
-8,000
Closed -$539K – 412
2019
Q3 		$539K Buy
+8,000
New +$616K 0.03% 252

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's BMRN Position: Q1 2026 in Review

LMR Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 1,594% in Q1 2026, buying an estimated $17.8M and bringing the position to 324,939 shares worth $18.4M. The position accounts for 0.04% of the portfolio, ranked #235.

LMR Partners first reported a position in BMRN in Q3 2019 and has held it in 19 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • LMR Partners held 324,939 shares of BioMarin Pharmaceuticals worth $18.4M as of Q1 2026.
  • LMR Partners bought 305,761 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $17.8M.
  • BioMarin Pharmaceuticals made up 0.04% of LMR Partners's portfolio in Q1 2026, its #235 holding.
  • LMR Partners first reported a position in BioMarin Pharmaceuticals in Q3 2019 and has held it in 19 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.